Search Results for: STK11

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ETV4 ETS variant transcription factor 4
  • MAPK6/MAPK4 signaling
  • Prostate cancer
  • Ewing's sarcoma
Novel FAIM2 Fas apoptotic inhibitory molecule 2
Novel FAM98B family with sequence similarity 98 member B
  • tRNA processing in the nucleus
Novel FBP1 fructose-bisphosphatase 1
  • Gluconeogenesis
  • Adenosine phosphate
  • 2,5-Anhydroglucitol-1,6-Biphosphate
  • {4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol
  • Mdl-29951
  • Fructose-6-phosphate
  • MB-07803
  • Managlinat dialanetil
  • N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE
  • 2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE
  • 2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE
  • 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE
  • Fructose-1,6-bisphosphatase deficiency
Novel FBP2 fructose-bisphosphatase 2
  • Gluconeogenesis
Novel FGFR4 fibroblast growth factor receptor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • FGFR4 mutant receptor activation
  • FGFR4 ligand binding and activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR4 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Heparin
  • Ponatinib
  • Lenvatinib
  • Infigratinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
Novel FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • Assembly of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel GLIS2 GLIS family zinc finger 2
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
Novel GNPDA1 glucosamine-6-phosphate deaminase 1
  • Glycolysis
  • Beta-D-Glucose
  • 2-Deoxy-2-Amino Glucitol-6-Phosphate
  • N-acetyl-D-glucosamine-6-phosphate
Novel GRM1 glutamate metabotropic receptor 1
  • G alpha (q) signalling events
  • Class C/3 (Metabotropic glutamate/pheromone receptors)
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Sensory perception of sweet, bitter, and umami (glutamate) taste
  • Glutamic acid
  • (S)-alpha-methyl-4-carboxyphenylglycine
Novel HERC2 HECT and RLD domain containing E3 ubiquitin protein ligase 2
  • SUMOylation of DNA damage response and repair proteins
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • G2/M DNA damage checkpoint
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel HGF hepatocyte growth factor
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • Drug-mediated inhibition of MET activation
  • Valproic acid
  • Heparin
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • ABT-510
  • Foretinib
Novel HIF1A hypoxia inducible factor 1 subunit alpha
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Cellular response to hypoxia
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Expression
  • PTK6 promotes HIF1A stabilization
  • Neddylation
  • STAT3 nuclear events downstream of ALK signaling
  • Regulation of PD-L1(CD274) transcription
  • Carvedilol
  • Hydralazine
  • 2-Methoxyestradiol
  • ENMD-1198
  • PX-478
  • FG-2216
  • Vadadustat
Novel HRAS HRas proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Novel IGFBP3 insulin like growth factor binding protein 3
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Post-translational protein phosphorylation
  • Alitretinoin
  • Mecasermin
Novel KAT2A lysine acetyltransferase 2A
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HATs acetylate histones
  • Notch-HLH transcription pathway
  • B-WICH complex positively regulates rRNA expression
  • Ub-specific processing proteases
  • RNA Polymerase I Transcription Initiation
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Cardiogenesis
  • Formation of WDR5-containing histone-modifying complexes
  • Formation of paraxial mesoderm
  • Coenzyme A
Novel KDELR2 KDEL endoplasmic reticulum protein retention receptor 2
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
Novel KLK7 kallikrein related peptidase 7
  • Degradation of the extracellular matrix
  • Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
  • L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide
Novel LATS2 large tumor suppressor kinase 2
  • Signaling by Hippo
Novel LEF1 lymphoid enhancer binding factor 1
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • Deactivation of the beta-catenin transactivating complex
  • Ca2+ pathway
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Repression of WNT target genes
  • Repression of WNT target genes
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates WNT signaling
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Cardiogenesis
  • Germ layer formation at gastrulation
  • Formation of paraxial mesoderm
  • Formation of axial mesoderm
  • Somitogenesis
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Etacrynic acid

Page 3 out of 14 pages